BiOptix, a life science tools company that provides an affordable and powerful solution for drug discovery scientists that require label-free, real-time detection of biomolecular interactions, today announced the release of a new study on the biophysical analysis of biotherapeutics done in collaboration with Indiana University, the National Defense Science and Engineering Graduate Fellowship and the National Institute of Allergy and Infectious Disease.
The research paper, titled “Symmetry Controlled Presentation of Bio-Active Molecules on the P22 VLP,” explores a new strategy for genetic protein binding for a virus-like particle (VLP) from salmonella typhimurium bacteriophage P22 as measured by the BiOptix 404pi Enhanced Surface Plasmon Resonance (E-SPR) instrument. The ability to precisely control the location and availability of a select protein offers a robust means to orchestrate responses to internally functionalized VLP’s within biological systems.
“This research provides important measurements for drug development scientists and provides a vital tool for vaccine research and development,” said Rick Whitcomb, President and CEO of BiOptix. “This is a perfect example of how strategic collaboration between research universities and industry is key to bringing new vaccine research to light; the BiOptix biosensor plays an integral role in this early stage pharmaceutical development.”
The ultra-sensitive BiOptix 404pi E-SPR detection platform offers precise measurement of kinetics, affinity constants and concentration, through an easy-to-use analytical software and two operating modes for higher throughput and experimental flexibility.
The full research report will be available at the American Association of Pharmaceutical Scientists National Biotech Conference in San Francisco June 8-10 at the BiOptix booth (#812), and is available to download on the BiOptix website.
About BiOptix
BiOptix offers an affordable and powerful solution for drug discovery scientists that require label-free real-time detection of biomolecular interactions. The unique SPR-enhanced instrumentation offers precise measurement of kinetics, affinity constants and concentration, proprietary easy-to-use analytical software, and two operating modes for higher throughput and experimental flexibility.
Based in Boulder, Colorado, BiOptix was founded in 2008 with the mission of making SPR instrumentation more accessible to drug discovery scientists. BiOptix partners with biotechnology, pharmaceutical and academic research organizations to make their drug development process more effective and productive. For more information about BiOptix, visit www.bioptix.com.
Patient-derived organoids: Transforming cancer research and personalized medicine